{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Tab+Tacrolimus", "query": { "intervention": "Oral Tab Tacrolimus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Tab+Tacrolimus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T02:35:59.705Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03289650", "title": "Extended Release Tacrolimus vs. Twice-Daily Tacrolimus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "End Stage Renal Disease", "Rejection of Renal Transplant" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lorenzo Gallon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 29, "start_date": "2017-09-05", "completion_date": "2021-02-23", "has_results": true, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03289650" }, { "nct_id": "NCT00402168", "title": "A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Transplant" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Cyclosporine A", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2007-01", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2017-01-05", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402168" }, { "nct_id": "NCT06120140", "title": "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amivantamab IV", "type": "DRUG" }, { "name": "Amivantamab SC", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Clindamycin", "type": "DRUG" }, { "name": "Chlorhexidine", "type": "DRUG" }, { "name": "Noncomedogenic skin moisturizer", "type": "OTHER" }, { "name": "Ruxolitinib", "type": "OTHER" }, { "name": "Tacrolimus", "type": "OTHER" }, { "name": "Zinc gluconate", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" }, { "name": "Timolol", "type": "DRUG" }, { "name": "Clobetasol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2024-02-16", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 28, "location_summary": "Chandler, Arizona • Duarte, California • Fullerton, California + 25 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120140" }, { "nct_id": "NCT00369382", "title": "Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Graft Rejection", "Kidney Failure" ], "interventions": [ { "name": "cyclosporine or tacrolimus", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2006-09", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2011-05-30", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 8, "location_summary": "Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369382" }, { "nct_id": "NCT00596947", "title": "Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Transplants and Implants" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "rabbit antithymocyte globulin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "19 Years to 74 Years" }, "enrollment_count": 18, "start_date": "2005-10", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00596947" }, { "nct_id": "NCT03380936", "title": "Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Kidney Transplant Rejection" ], "interventions": [ { "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]", "type": "DRUG" }, { "name": "Plasma Exchange and IVIG (Intravenous Immunoglobulin )", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 4, "start_date": "2018-01-17", "completion_date": "2019-10-16", "has_results": false, "last_update_posted_date": "2020-10-27", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03380936" }, { "nct_id": "NCT00608244", "title": "Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Failure" ], "interventions": [ { "name": "LCP Tacro", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 59, "start_date": "2007-11", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2015-08-28", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00608244" }, { "nct_id": "NCT03386539", "title": "Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pediatric Heart Transplantation", "Immunosuppression", "Chronic Kidney Diseases", "Cardiac Allograft Vasculopathy", "Heart Transplant Failure and Rejection", "Post-transplant Lymphoproliferative Disorder", "Heart Transplant Infection" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 211, "start_date": "2018-01-29", "completion_date": "2023-05-17", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386539" }, { "nct_id": "NCT00496483", "title": "Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Failure" ], "interventions": [ { "name": "LCP Tacro (tacrolimus)", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2007-07", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2015-07-23", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Houston, Texas", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496483" }, { "nct_id": "NCT00765661", "title": "Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Failure", "Renal Failure" ], "interventions": [ { "name": "Tacrolimus (Tacro™)", "type": "DRUG" }, { "name": "Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2008-09", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-09-20T02:35:59.705Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00765661" } ] }